UBS Group
BIAF icon

UBS Group’s bioAffinity Technologies BIAF Stock Holding History

UBS Group’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Sell
4,204
-5,010
-54% -$10.2K ﹤0.01% 9193
2026
Q1 		$35.3K Buy
+9,214
New +$14.9K ﹤0.01% 7592
2025
Q4 		– Sell
-143
Closed -$423 – 10518
2025
Q3 		$423 Buy
143
+142
+14,200% +$1.13K ﹤0.01% 9683
2025
Q2 		$7 Buy
+1
New +$11 ﹤0.01% 10162
2024
Q3 		– Sell
-320
Closed -$20.7K – 9506
2024
Q2 		$20.7K Buy
+320
New +$22.2K ﹤0.01% 7279
2023
Q4 		– Sell
-2
Closed -$76 – 9316
2023
Q3 		$76 Sell
2
-1
-33% -$51 ﹤0.01% 8938
2023
Q2 		$174 Sell
3
-77
-96% -$4.25K ﹤0.01% 8426
2023
Q1 		$4.55K Sell
80
-139
-63% -$8.04K ﹤0.01% 8174
2022
Q4 		$10.5K Buy
219
+55
+34% +$4.18K ﹤0.01% 8499
2022
Q3 		$14K Buy
+164
New +$20.7K ﹤0.01% 7893

Other funds holding BIAF

JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's BIAF Position: Q2 2026 in Review

UBS Group reduced its bioAffinity Technologies (BIAF) stake by 54% in Q2 2026, selling an estimated $10.2K and leaving 4,204 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #9193.

UBS Group first reported a position in BIAF in Q3 2022 and has held it in 10 quarters since. The position peaked at $35.3K in Q1 2026. 14 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • UBS Group held 4,204 shares of bioAffinity Technologies worth $3.41K as of Q2 2026.
  • UBS Group sold 5,010 bioAffinity Technologies shares in Q2 2026, an estimated $10.2K.
  • bioAffinity Technologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9193 holding.
  • UBS Group first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 10 quarters since.
  • UBS Group's bioAffinity Technologies position peaked at $35.3K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.